Nadia's Feed
Mar 2, 2015

NXP to buy Freescale Semiconductor, merge operations in $40 billion deal

NEW YORK (Reuters) – Chip maker NXP Semiconductors NV (NXPI.O: Quote, Profile, Research, Stock Buzz) has agreed to buy smaller peer Freescale Semiconductor Ltd (FSL.N: Quote, Profile, Research, Stock Buzz) and merge operations in a deal valuing the combined company at over $40 billion.

The deal, announced by the pair late on Sunday and first reported by Reuters, will make the business the industry leader within the auto and industrial semiconductor markets.

Mar 1, 2015

NXP nears deal for Freescale Semiconductor -sources

March 1 (Reuters) – NXP Semiconductors NV is close
to a deal to acquire smaller peer Freescale Semiconductor Ltd
in a $40 billion cash and stock merger that will reshape
the semiconductor industry, according to two people familiar
with the matter.

Such a deal would represent the clearest sign yet that
semiconductor companies are regaining the confidence required to
pursue big mergers at a time when their major clients, such as
mobile phone manufacturers, seek to consolidate suppliers.

Mar 1, 2015

Exclusive: NXP Semiconductors nears deal for Freescale Semiconductor – sources

By Nadia Damouni

(Reuters) – NXP Semiconductors NV is close to a deal to acquire smaller peer Freescale Semiconductor Ltd in a $40 billion cash and stock merger that will reshape the semiconductor industry, according to two people familiar with the matter.

Such a deal would represent the clearest sign yet that semiconductor companies are regaining the confidence required to pursue big mergers at a time when their major clients, such as mobile phone manufacturers, seek to consolidate suppliers.

Feb 27, 2015

EMC to hold on to VMware stake – sources

NEW YORK (Reuters) – EMC Corp (EMC.N: Quote, Profile, Research) has decided against spinning off its majority stake in VMware Inc (VMW.N: Quote, Profile, Research) after reviewing the idea over the last several months following pressure from activist investor Elliott Management Corp, three sources close to the matter said.

Elliott, which owns a 2.2 percent stake in EMC, had called on the Boston-based data storage company to spin off its VMware stake last year as part of a wider public campaign. Last month, Elliott agreed to refrain from agitating against EMC for eight months in exchange for adding two new independent directors on the company’s board.

Feb 27, 2015

Exclusive: EMC to hold on to VMware stake – sources

NEW YORK (Reuters) – EMC Corp (EMC.N: Quote, Profile, Research, Stock Buzz) has decided against spinning off its majority stake in VMware Inc (VMW.N: Quote, Profile, Research, Stock Buzz) after reviewing the idea over the last several months following pressure from activist investor Elliott Management Corp, three sources close to the matter said.

Elliott, which owns a 2.2 percent stake in EMC, had called on the Boston-based data storage company to spin off its VMware stake last year as part of a wider public campaign. Last month, Elliott agreed to refrain from agitating against EMC for eight months in exchange for adding two new independent directors on the company’s board.

Feb 20, 2015

Drugmaker Valeant close to buying Salix: source

NEW YORK (Reuters) – Valeant Pharmaceuticals International Inc (VRX.TO: Quote, Profile, Research, Stock Buzz) is close to a deal to acquire bowel drug maker Salix Pharmaceuticals Ltd (SLXP.O: Quote, Profile, Research, Stock Buzz) for around $160 per share, according to a person directly familiar with the matter.

An agreement could come as early as next week, the source said on Friday, who requested not to be identified as the matter is confidential.

Feb 14, 2015

Exclusive: Informatica seeks advisers to revive sale process – sources

By Nadia Damouni, Liana B. Baker and Greg Roumeliotis

(Reuters) – Enterprise software maker Informatica Corp (INFA.O: Quote, Profile, Research, Stock Buzz) is looking to hire new financial advisers that will help it revive a sale process and defend itself from activist hedge fund Elliott Management Corp, according to people familiar with the matter.

An auction for Informatica run by investment banking boutique Qatalyst Partners LP was put on hold early last month after interest received from private equity firms, including a consortium led by Hellman & Friedman LLC, failed to lead to a deal, the people said this week.

Feb 7, 2015

Exclusive: Top Fox investors seek to convert voting shares, Murdoch may benefit

NEW YORK (Reuters) – Several top investors in Twenty-First Century Fox Inc are pressing for the right to swap their voting shares for ordinary shares, which are trading at an unusual premium, even though the move could hand even more control of the company to Rupert Murdoch, according to people familiar with the matter.

Fox’s dual-class share structure already gives the 83-year-old media mogul control over 39.7 percent of voting rights, even though he and his family hold only a 12 percent equity stake.

Feb 6, 2015

Exclusive: Top Fox investors seek to convert voting shares, Murdoch may benefit – sources

NEW YORK (Reuters) – Several top investors in Twenty-First Century Fox Inc are pressing for the right to swap their voting shares for ordinary shares, which are trading at an unusual premium, even though the move could hand even more control of the company to Rupert Murdoch, according to people familiar with the matter.

Fox’s dual-class share structure already gives the 83-year-old media mogul control over 39.7 percent of voting rights, even though he and his family hold only a 12 percent equity stake.

Feb 3, 2015

How the Actavis deal upended Allergan No. 2′s CEO ambitions

NEW YORK, Feb 3 (Reuters) – For two decades, Allergan Inc
president Doug Ingram labored to transform the
Botox-maker from a sleepy eye care upstart to a global
aesthetics giant. He was just a few months away from getting the
top job when a merger deal with Actavis Plc in November
thwarted his ambitions.

Ingram has now accepted an advisory role to facilitate the
merger and will soon be looking for a job outside the combined
company. Allergan’s derailed succession plans, disclosed by
Ingram and other top executives in interviews with Reuters,
underscore how corporate mergers can leave even some of the
industry’s top executives in the cold.